000963 华东医药
交易中 07-29 10:39:18
资讯
新帖
简况
华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元
智通财经 · 07-20
华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元
7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股
证券之星 · 07-17
7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股
华东医药：DR10624为长效三靶点激动剂
证券之星 · 07-17
华东医药：DR10624为长效三靶点激动剂
华东医药（000963）披露控股子公司获得药物临床试验批准通知书，7月13日股价下跌0.75%
证券之星 · 07-13
华东医药（000963）披露控股子公司获得药物临床试验批准通知书，7月13日股价下跌0.75%
华东医药最新公告：控股子公司DR10624注射液获临床试验批准
证券之星 · 07-13
华东医药最新公告：控股子公司DR10624注射液获临床试验批准
华东医药：HDM2024在有效性、安全性方面具备差异化潜力
证券之星 · 07-10
华东医药：HDM2024在有效性、安全性方面具备差异化潜力
华东医药：HDM1002体重管理适应症中国临床III期研究预计于2026年Q3获得关键数据读出
证券之星 · 07-10
华东医药：HDM1002体重管理适应症中国临床III期研究预计于2026年Q3获得关键数据读出
华东医药（000963）披露2026年第一季度报告（英文版），7月8日股价下跌1.03%
证券之星 · 07-08
华东医药（000963）披露2026年第一季度报告（英文版），7月8日股价下跌1.03%
华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%
证券之星 · 07-01
华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%
华东医药：芮妥欣®铺货推进符合前期规划
证券之星 · 07-01
华东医药：芮妥欣®铺货推进符合前期规划
华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排
证券之星 · 07-01
华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排
华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出
证券之星 · 07-01
华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出
华东医药：本次集采最终影响存在不确定性
证券之星 · 06-30
华东医药：本次集采最终影响存在不确定性
6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股
证券之星 · 06-29
6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%
证券之星 · 06-25
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
证券之星 · 06-25
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书
格隆汇 · 06-24
华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书
华东医药最新公告：全资子公司皮肤治疗仪V30获批上市
证券之星 · 06-24
华东医药最新公告：全资子公司皮肤治疗仪V30获批上市
股市必读：华东医药（000963）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：华东医药（000963）6月16日董秘有最新回复
华东医药：公司目前暂无BTK-PROTAC 管线推进计划
证券之星 · 06-16
华东医药：公司目前暂无BTK-PROTAC 管线推进计划
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":29.41,"timestamp":1785292758000,"preClose":28.91,"halted":0,"volume":9967386,"delay":0,"changeRate":0.0173,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"交易中","change":0.5,"latestTime":"07-29 10:39:18","open":28.94,"high":29.58,"low":28.93,"amount":292000000,"amplitude":0.0225,"askPrice":29.45,"askSize":87,"bidPrice":29.42,"bidSize":9,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1785295800000},"marketStatusCode":2,"adr":0,"adjPreClose":28.91,"symbolType":"stock","openAndCloseTimeList":[[1785288600000,1785295800000],[1785301200000,1785308400000]],"highLimit":31.8,"lowLimit":26.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.97,"roa":"--","peRate":14.728566,"roe":"3.97%","epsLYR":1.9484,"committee":0.464996,"marketValue":51577000000,"turnoverRate":0.0057,"status":0,"floatMarketCap":51556000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2652261223","title":"华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652261223","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652261223?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:54","pubTimestamp":1784519697,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药(000963.SZ)发布公告，公司董事长吕梁先生提议，在符合相关法律法规及《公司章程》规定的利润分配政策前提下，依据公司于2026年05月20日召开的2025年度股东会对董事会的授权，提议以公司未来实施2026年中期利润分配方案的股权登记日的总股本为基数，向全体股东每10股派3.50元现金(含税)，不送红股，不以资本公积转增股本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0188","BK0187","LU1969619763.USD","LU2328871848.SGD","BK0183","BK0175","000963","BK0196","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405038","title":"7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405038","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652405038?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:38","pubTimestamp":1784277532,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日华东医药跌5.82%，收盘报30.1元，换手率2.13%，成交量37.3万手，成交额11.41亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华目前规模为151.77亿元，最新净值0.908，较上一交易日下跌0.27%，近一年上涨6.89%。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0183","159316","LU2328871848.SGD","BK0188","BK0132","BK0196","LU1969619763.USD","BK0175","BK0187","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652457473","title":"华东医药：DR10624为长效三靶点激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2652457473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652457473?lang=zh_cn&edition=full","pubTime":"2026-07-17 08:43","pubTimestamp":1784248986,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药07月16日在投资者关系平台上答复投资者关心的问题。近期关注到DR10624已布局高甘油三酯血症、MASLD、MASH、肥胖、2型糖尿病及HFpEF/HFmrEF等多个适应症。DR10624 为长效三靶点激动剂，具备代谢综合调节潜力。目前该产品正围绕高甘油三酯血症、MASLD、HFpEF/HFrEF等多适应症进行开发。公司将结合临床研究进展持续评估拓展新适应症，力争打造覆盖内分泌代谢及心血管疾病的差异化产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700007597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0132","BK0188","BK0187","BK0175","BK0209","LU2328871848.SGD","BK0196","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117189","title":"华东医药（000963）披露控股子公司获得药物临床试验批准通知书，7月13日股价下跌0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651117189?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:15","pubTimestamp":1783952123,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，华东医药报收于29.16元，较前一交易日下跌0.75%，最新总市值为511.39亿元。该股当日开盘29.16元，最高29.47元，最低28.85元，成交额达5.37亿元，换手率为1.05%。近日，华东医药控股子公司浙江道尔生物科技有限公司收到中国NMPA通知，其申报的DR10624注射液临床试验申请已获批准，拟用于治疗成人射血分数保留/射血分数轻度降低的心力衰竭。本次获批对公司近期业绩无重大影响，后续研发及上市存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300040071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0132","LU1969619763.USD","BK0187","LU2328871848.SGD","000963","BK0196","BK0188","BK0175","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651433113","title":"华东医药最新公告：控股子公司DR10624注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651433113","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651433113?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:30","pubTimestamp":1783938622,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司控股子公司道尔生物收到中国NMPA通知，其申报的DR10624注射液临床试验申请已获批准，适应症为治疗成人射血分数保留/射血分数轻度降低的心力衰竭。该药物为全球首创长效三特异性激动剂，此次获批将提升公司在心血管和内分泌治疗领域的核心竞争力，但对近期业绩无重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300029425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","LU1969619763.USD","LU2328871848.SGD","BK0209","BK0183","BK0188","BK0187","BK0132","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185670","title":"华东医药：HDM2024在有效性、安全性方面具备差异化潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650185670?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:51","pubTimestamp":1783673465,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的HDM2024和百利天恒已上市的同靶点药品相比有什么优势吗，为什么进度落后这么多，依然跟进去研发这个靶点华东医药回复：您好！根据现有数据，HDM2024与同类药物相比，在有效性、安全性方面具备差异化潜力。公司布局该靶点，系基于对靶点临床价值、市场需求及自身技术平台优势的综合研判，看好该赛道长期临床与商业化空间，后续将按研发节点适时对外披露进展。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0132","BK0175","LU1969619763.USD","LU2328871848.SGD","BK0183","000963","BK0187","BK0196","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650549185","title":"华东医药：HDM1002体重管理适应症中国临床III期研究预计于2026年Q3获得关键数据读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2650549185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650549185?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:48","pubTimestamp":1783673293,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，1002的减肥三期数据，q3会公布吗华东医药回复：您好！HDM1002体重管理适应症中国临床III期研究预计于2026年Q3获得关键数据读出，预计2026年Q4递交NDA申请。后续公司将结合项目进展，择机通过国际权威学术会议、公司公告或官方新闻等渠道对外披露相关数据，相关信息敬请持续留意公司后续发布内容。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","LU2328871848.SGD","BK0187","BK0196","LU1969619763.USD","BK0188","BK0183","BK0132","000963","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649946139","title":"华东医药（000963）披露2026年第一季度报告（英文版），7月8日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649946139","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649946139?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:27","pubTimestamp":1783520836,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，华东医药报收于28.93元，较前一交易日下跌1.03%，最新总市值为507.36亿元。该股当日开盘29.3元，最高29.81元，最低28.92元，成交额达5.07亿元，换手率为0.99%。公告显示，公司2026年第一季度实现营业收入111.83亿元，同比增长4.17%；归属于上市公司股东的净利润10.02亿元，同比增长9.56%；扣除非经常性损益后的净利润9.90亿元，同比增长10.30%。基本每股收益0.5715元，同比增长9.40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","000963","LU1969619763.USD","BK0175","BK0209","LU2328871848.SGD","BK0188","BK0132","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648854151","title":"华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648854151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648854151?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:30","pubTimestamp":1782916235,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，华东医药报收于29.57元，较前一交易日上涨5.16%，最新总市值为518.58亿元。近日，华东医药股份有限公司发布公告，控股股东中国远大集团有限责任公司将其持有的22,500,000股公司股份质押给中国中金财富证券有限公司，用于续贷质押。同时，远大集团解除质押16,330,000股。本次质押及解除质押后，远大集团累计质押股份为144,810,000股，占其所持股份比例19.81%，占公司总股本比例8.26%。已质押股份无限售和冻结情况，未质押股份也无限制情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0132","BK0188","BK0187","BK0175","BK0209","LU2328871848.SGD","BK0196","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515126","title":"华东医药：芮妥欣®铺货推进符合前期规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515126","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515126?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894254,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药07月01日在投资者关系平台上答复投资者关心的问题。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美矩阵扩大市场覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0209","BK0187","BK0175","BK0183","BK0132","BK0196","LU1969619763.USD","BK0188","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648951543","title":"华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2648951543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648951543?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894250,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，结合公司经营情况，市场普遍预判半年报业绩变动幅度大概率未达到深交所强制披露业绩预告的标准。想咨询公司：即便无强制披露要求，管理层是否会考虑自愿发布2026年半年度业绩预告，提前向投资者反馈医美、GLP-1、创新药等板块上半年经营情况？感谢解答。华东医药回复：您好！目前公司暂无自愿披露2026年半年度业绩预告的相关安排。关于半年度业绩的详细情况，敬请关注公司后续披露的正式定期报告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","LU2328871848.SGD","BK0187","BK0196","LU1969619763.USD","BK0188","BK0183","BK0132","000963","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515435","title":"华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515435?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894248,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！我想问的是注射用 HDM2017 晚期恶性实体瘤适应症的临床试验一期结果什么时候公布？是在学术会议期间发布还是以公告的形式发布？谢谢！华东医药回复：您好！HDM2017的单药概念验证初步临床数据预计今年第四季度读出。后续公司将结合项目进展，择机通过国际权威学术会议、公司公告或官方新闻等渠道对外披露相关数据，相关信息敬请持续留意公司后续发布内容。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","LU2328871848.SGD","BK0187","BK0196","LU1969619763.USD","BK0188","BK0183","BK0132","000963","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647852585","title":"华东医药：本次集采最终影响存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2647852585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647852585?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:01","pubTimestamp":1782781266,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：占公司仿制药板块销售额过半的几款核心产品都进入十二批集采，公司怎么考虑，会对27年的收入产生多大影响华东医药回复：您好！本次集采最终影响取决于具体竞价规则、公司产品是否中标及中标价格、约定采购量、竞争格局等因素，存在不确定性，目前尚无法预判对收入的具体影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000008885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0132","000963","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0175","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322635","title":"6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322635?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:48","pubTimestamp":1782722939,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日华东医药涨8.75%，收盘报28.72元，换手率2.16%，成交量37.94万手，成交额10.52亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","159316","BK0175","BK0183","BK0209","LU1969619763.USD","BK0187","BK0132","LU2328871848.SGD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809345","title":"华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809345?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:17","pubTimestamp":1782397035,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，华东医药报收于27.89元，较前一交易日下跌1.27%，最新总市值为489.12亿元。近日，华东医药披露公告显示，2026年6月24日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用HDM2017联合治疗晚期结直肠癌的临床试验申请获得批准。该药此前已获中国和美国临床试验批准，部分适应症获FDA孤儿药资格认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0132","000963","BK0188","BK0196","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646901871","title":"华东医药最新公告：全资子公司注射用HDM2017获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646901871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646901871?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:19","pubTimestamp":1782382793,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，注射用HDM2017联合治疗晚期结直肠癌的临床试验申请获得批准。该药物为靶向钙黏蛋白17的新型抗体药物偶联物，此前已获中美两国晚期恶性实体瘤适应症临床试验批准及美国FDA三项孤儿药资格认定。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500033918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","LU2328871848.SGD","BK0196","BK0132","BK0187","BK0175","000963","LU1969619763.USD","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891765","title":"华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891765?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:11","pubTimestamp":1782295883,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0132","BK0183","BK0188","BK0209","000963","BK0175","BK0196","BK0187","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891036","title":"华东医药最新公告：全资子公司皮肤治疗仪V30获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891036","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891036?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:11","pubTimestamp":1782295870,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司全资子公司Viora收到国家药监局签发的《医疗器械注册证》，其三类医疗器械皮肤治疗仪V30获批上市。V系列产品兼容性强，可适配未来Viora开发的新技术。V30已获得美国FDA、欧盟CE注册认证。同系列产品V20已于2024年9月获得NMPA批准上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400034269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU2328871848.SGD","BK0175","LU1969619763.USD","000963","BK0183","BK0196","BK0187","BK0188","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644761998","title":"股市必读：华东医药（000963）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644761998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644761998?lang=zh_cn&edition=full","pubTime":"2026-06-17 01:16","pubTimestamp":1781630170,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，华东医药报收于28.26元，下跌2.55%，换手率0.68%，成交量11.99万手，成交额3.41亿元。董秘最新回复投资者： 公司年报里就披露10624在临床三期中，怎么都过去一个多月了，还没看到三期临床的注册信息呢董秘： 您好！控股子公司道尔生物专注基于多结构域的多特异性生物药的创新开发，依托自有技术平台差异化布局创新ADC。当日关注点交易信息汇总：6月16日主力资金净流出3477.84万元，散户资金净流入3881.89万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700000514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0209","BK0183","BK0196","BK0188","BK0175","LU1969619763.USD","BK0132","000963","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643445737","title":"华东医药：公司目前暂无BTK-PROTAC 管线推进计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2643445737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643445737?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:36","pubTimestamp":1781598969,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：罗氏重金买了一款btk protac，公司几年前就曾披露了同靶点同机制的管线，但还没推进到临床，请问公司后续还会推进吗，如果推进，预计什么时候IND；如果不推进，公司是作何考虑华东医药回复：您好！公司目前暂无BTK-PROTAC 管线推进计划。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600028946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","LU1969619763.USD","BK0132","BK0188","BK0196","LU2328871848.SGD","000963","BK0183","BK0209","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785292761977,"stockEarnings":[{"period":"1week","weight":-0.0641},{"period":"1month","weight":0.0947},{"period":"3month","weight":-0.1198},{"period":"6month","weight":-0.1988},{"period":"1year","weight":-0.3213},{"period":"ytd","weight":-0.2516}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}